The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients

Journal of Clinical Psychiatry

Volumn 60, Issue 5, 1999, Pages 318-325

  Raskind, Murray A ^a,c   Cyrus, Pamela A ^b   Ruzicka, Bianca B ^b   Gulanski, Barbara I ^b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b BAYER CORPORATION   (United States)

^c VA Puget Sound Heath Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRIFONATE; PLACEBO;

ABDOMINAL PAIN; AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; FEMALE; HUMAN; LEG CRAMP; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; TREATMENT OUTCOME;

EID: 0033060809     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0510     Document Type: Article

References (50)

1. Hebert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995;273:1354-1359
2. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989;262:2551-2556
3. Cummings JL, Benson DF. Dementia: A Clinical Approach. 2nd ed. Boston, Mass: Heinemann-Butterworth: 1992
4. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease [letter]. Lancet 1976;2:1403
5. Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-126
6. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978;2:1457-1459
7. Wilcock GK, Esiri MM, Bowen DM, et al. Alzheimer's disease: correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 1982;57:407-417
8. Sunderland T, Tariot PN, Cohen RM, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. Arch Gen Psychiatry 1987;44:418-426
9. Drachman DA. Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 1977;27:783-790
10. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996;47:876-883
11. Mega M, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130-135
12. Cummings JL, Gorman DG, Shapira J. Physostigmine ameliorates the delusions in Alzheimer's disease. Biol Psychiatry 1993;33:536-541
13. Swearer JM, Drachman DA, O'Donnell BF, et al. Troublesome and disruptive behaviors in dementia. J Am Geriatr Soc 1988;36:784-790
14. Colenda CC III. Agitation: a conceptual overview. In: Lawlor BA, ed. Behavioral Complications in Alzheimer's Disease. Washington, DC: American Psychiatric Press; 1995:3-17
15. Gorman DG, Read S, Cummings JL. Cholinergic therapy of behavioral disturbances in Alzheimer's disease. Neuropsychiatry Neuropsychol Behav Neurol 1993;6:229-234
16. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol 1996;9:1-6
17. Sunderland T, Tariot PN, Newhouse PA. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res 1988;472:371-389
18. Penn RD, Martin EM, Wilson RS, et al. Intraventricular bethanechol infusion for Alzheimer's disease: results of double-blind and escalating-dose trials. Neurology 1988;38:219-222
19. Bodick NC, Offen WW, Levey A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch Neurol 1997;54:465-473
20. Raskind MA, Sadowsky CH, Sigmund WR, et al. Effect of tacrine on language, praxis and noncognitive behavioral problems in Alzheimer's disease. Arch Neurol 1997;54:836-840
21. Galasko DR, Thai LJ. Cholinomimetic agents. In: Cummings JL, Miller BL, eds. Alzheimer's Disease: Treatment and Long-Term Management. New York, NY: Marcel Dekker; 1990:23-36
22. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1002;268:2523-2529
23. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991
24. Rogers SL, Friedhoff LT, and the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303
25. Nordgren I, Bergstrom M, Holmstedt B, et al. Transformation and action of metrifonate. Arch Toxicol 1978;41:31-41
26. Hinz VC, Grewig S, Schmidt BH. Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos. Neurochem Res 1996; 21:331-337
27. Hinz V, Grewig S, Schmidt BH. Metrifonate and dichlorvos: effects of a single oral administration on cholinesterase activity in rat brain and blood. Neurochem Res 1996;21:339-345
28. Schmidt BH, Hinz VC, Blokland A, et al. Preclinical pharmacology of metrifonate: a promise for Alzheimer therapy. In: Becker R, Giacobini E, Robert P, eds. Alzheimer Disease: From Molecular Biology to Therapy. Boston, Mass: Birkhäuser; 1996:217-221
29. Becker RE, Colliver J, Elble R, et al. Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer disease: report of an open trial. Drug Dev Res 1990;19:425-434
30. Cummings JL, Cyrus P, Bieber F, et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998;50:1214-1221
31. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral and global function in Alzheimer's disease patients. Neurology 1998;50:1222-1230
32. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944
33. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
34. Rosen WG, Terry RD, Fuld P, et al. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488
35. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised. Washington, DC: American Psychiatric Association; 1994
36. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364
37. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314
38. Gelinas I. Development, content validation and testing of reliability of a disability assessment in dementia of the Alzheimer's type. In: Programme and Abstracts for the Fifth Research Colloquium in Rehabilitation; May 1994; Montreal, Canada
39. Gelinas L, Gauthier L, Wood-Dauphinee S, et al. Assessment of functional disability in Alzheimer's disease [abstract]. Revue Canadienne d'Ergo-therapie 1995;62:15
40. Knopman DS, Knapp MJ, Gracon SI, et al. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44:2315-2321
41. Reisberg B, Ferris SH, De Leon MJ, et al. A Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-1139
42. National adverse drug reaction directory: "COSTART." Rockville, Md: US Dept Health Education Welfare, Public Health Service, Food and Drug Administration; 1989. Publication PB90-114026AS.
43. Salmon DP, Thal LJ, Butters N, et al. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of three standardized mental status examinations. Neurology 1990;40:1225-1230
44. Decker MW, McGaugh JL. The role of the interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 1991;7:151-168
45. Sarter M. Neuronal mechanisms of the attentional dysfunctions in senile dementia and schizophrenia: two sides of the same coin? Psychopharmacology (Berl) 1994;114:539-550
46. Szymusiak R. Magnocellular nuclei of the basal forebrain: substrates of sleep and arousal regulation. Sleep 1995;18:478-500
47. Teri L, Borson S, Kiyak HA, et al. Behavioral disturbance, cognitive dysfunction and functional skill: prevalence and relationship in Alzheimer's disease. J Am Geriatr Soc 1989;37:109-116
48. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 1989;146:577-587
49. Borson S, Raskind, MA. Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease. Neurology 1997;48 (suppl 6):S17-S24
50. Tracy JW, Webster LT Jr. Drugs used in the chemotherapy of helminthiasis. In: Goodman LS, Limbird LE, Molinoff PB, et al, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:1009-1026